Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$5.60M$5.60M+56.6% vs Q2 2025 Net Income-$534.00K-$534.00KN/M vs Q2 2025 EPS Diluted-$0.32-$0.32N/M vs Q2 2025 Gross Profit$2,120,000+55.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$635,000N/M Free Cash Flowderived-$645,000N/M Margins · derivedGross margin37.8%−0.2 pt vs Q2 2025
Operating margin-6.0%+17.7 pt vs Q2 2025
Net margin-9.5%+7.5 pt vs Q2 2025
ended Sep 30, 2025 · filed Nov 4, 2025 · 35 d after period end